Scarica l'app Stockscreener
658.02
0.93%
6.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$651.98
Aprire:
$650
Volume 24 ore:
1.58M
Relative Volume:
0.76
Capitalizzazione di mercato:
$243.30B
Reddito:
$45.20B
Utile/perdita netta:
$6.87B
Rapporto P/E:
36.18
EPS:
18.1888
Flusso di cassa netto:
$6.75B
1 W Prestazione:
-2.77%
1M Prestazione:
+7.90%
6M Prestazione:
+32.64%
1 anno Prestazione:
+25.38%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$635.32
$694.33
Portata 52W:
$435.27
$694.33
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
658.02 | 243.30B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
219.81 | 154.52B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.71 | 57.76B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
170.54 | 48.08B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
259.88 | 42.78B | 16.63B | 1.39B | 2.12B | 8.0674 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-09-03 | Iniziato | CLSA | Outperform |
| 2026-06-26 | Ripresa | Bernstein | Mkt Perform |
| 2026-06-11 | Iniziato | Piper Sandler | Neutral |
| 2026-06-03 | Downgrade | HSBC Securities | Buy → Hold |
| 2026-06-02 | Ripresa | Wolfe Research | Outperform |
| 2026-05-15 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 Billion - GlobeNewswire Inc.
Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research
JPMorgan Adds AmEx, Thermo Fisher and Liberty Energy to October Overweight Picks - BigGo Finance
Thermo Fisher Scientific stock heads into October 21 results after a 2.27 percent drop - AD HOC NEWS
Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook - Yahoo Finance
Barclays Adjusts Thermo Fisher Scientific Price Target to $750 From $650, Maintains Overweight Rating - marketscreener.com
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewswire Inc.
Preparations begin for Quantum BioPharma's planned Phase 2 multiple sclerosis drug trial - Stock Titan
Exclusive: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial - Benzinga
Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 - BioSpace
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 - Business Wire
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific - Zacks Investment Research
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific - TradingView
Thermo Fisher Scientific Inc (TMO) Stock Up 3.4% but GF Value Sa - GuruFocus
Thermo Fisher Scientific Inc Stock (TMO) Closed Up by 3.35% on Oct 5: Key Drivers Unveiled - TradingKey
Thermo Fisher Scientific accelerates market access by prioritizing the right KOLs - MedTech Dive
Here’s How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years - Benzinga
Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study - Business Wire
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity - GlobeNewswire Inc.
Cell and Gene Therapy Biomanufacturing MarketSize, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 Billion - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Global Methyl Grignard Reagent MarketStrategic Forecast, 2026-2032 | Pharmaceutical Demand, AI Process Control, and Resilient Supply Chains Unlock Growth Opportunities - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. (TMO) options chain - Yahoo Finance Australia
Thermo Fisher Scientific Inc (TMO) Shares Fall 3.3% -- What GF S - GuruFocus
Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatch
Thermo Fisher Scientific Inc Stock (TMO) Closed Down by 3.34% on Oct 1: What Signal Does It Send? - tradingkey.com
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Continuous Bioprocessing Technologies MarketGlobal Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR - GlobeNewswire Inc.
Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors? - Simply Wall Street
Thermo Fisher Scientific Inc (TMO) Stock Forecasts - Yahoo Finance
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Thermo Fisher Scientific Inc (TMO) Stock Up 0.1% but GF Value Sa - gurufocus.com
Thermo Fisher (TMO) director's deferred stock units total 2,846.55 after a quarterly credit - Stock Titan
At $675 per unit, a Thermo Fisher (TMO) director was credited with 62.96 stock units. - Stock Titan
Director Karen S. Lynch holds 398.7 deferred stock units at Thermo Fisher Scientific (TMO) after the credit. - Stock Titan
Thermo Fisher (TMO) credits director pay as stock units at $675 each. - Stock Titan
Director R. Alexandra Keith holds 1,377.65 stock units at Thermo Fisher (TMO) after a plan credit. - Stock Titan
Thermo Fisher Scientific stock trades at EUR 596.90 before October 21 results - AD HOC NEWS
Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run - Yahoo Finance
Thermo Fisher Launches Nicolet RaptIR X FTIR Microscope - Contract Pharma
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Press Release: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026 - Moomoo
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026 - Business Wire
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno - markets.businessinsider.com
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno - Yahoo Finance
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno - Yahoo Finance UK
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Thermo Fisher Scientific Inc Azioni (TMO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pettiti Gianluca | Officer |
Aug 31 '26 |
Proposed Sale |
614.38 |
4,133 |
2,539,233 |
0 |
| Pettiti Gianluca | President & COO |
Aug 31 '26 |
Sale |
614.38 |
4,133 |
2,539,233 |
23,216 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Sale |
627.05 |
275 |
172,439 |
123,925 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Option Exercise |
309.63 |
275 |
85,148 |
124,200 |
| CASPER MARC N | Officer |
Aug 24 '26 |
Proposed Sale |
627.05 |
275 |
172,438 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 21 '26 |
Sale |
626.92 |
10,000 |
6,269,153 |
123,925 |
| CASPER MARC N | Officer |
Aug 21 '26 |
Proposed Sale |
626.91 |
10,000 |
6,269,123 |
0 |
| CASPER MARC N | Officer |
Aug 20 '26 |
Proposed Sale |
629.27 |
10,000 |
6,292,653 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
1.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):